San Francisco, June 1, 2022 – Recardio Inc., a late stage clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the FDA concurs with Recardio’s pivotal Heal-MI Phase 3 trial design with Dutogliptin in Acute Myocardial Infarction.
Recardio’s Phase 2 trial results demonstrated the excellent safety profile of its lead drug dutogliptin along with data suggesting potential positive effects on cardiac function and were presented in May at theWorld Congress onAcute Heart Failure 2022 in Madrid. Along with data suggesting potential positive effects on cardiac function, it was concluded that a pivotal study of this therapeutic approach in a large, adequately powered NDA-enabling study is warranted.
After reviewing the Phase 2 trial results, FDA agreed with the proposed trial design and sample size for the pivotal Phase 3 trial of dutogliptin in co-administration with filgrastim in early recovery post-myocardial infarction. A comparable agreement was also reached with the EMA.
The global pivotal trial, named HEAL-MI, will enroll 4.000 acute myocardial patients with STEMI but not specified left ventricular ejection function (LVEF) and with facilitated screening procedures, which will accelerate the total enrollment. The primary endpoint is a combined clinical endpoint with a Quality-of-Life evaluation as a secondary endpoint.
Based on this advice preparations are already under way for the trial that is intended to start in the course of 2022 and and will enroll patients in the key global regions – US, Europe and China.
Dr. Roman Schenk, RECARDIO President commented: “We appreciate the positive agency feedback and are looking forward contributing with this HEAL-MI pivotal trial to further therapeutic patients for the respective patients with myocardial infarction.”
Recardio Inc. is a late clinical-stage life science company focusing on therapies for cardiovascular and other diseases. The company is located in San Francisco, California, and is having its operations in USA and Europe. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor having demonstrated significant effects in activating various chemokines like SDF-1, a protein that is critical for cardiac regeneration resulting in healing cardiac tissue after an injury.
Recardio is currently initiating its global pivotal Phase 3 clinical program in acute myocardial infarction for market authorization in major markets and will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases.
In addition, other development programs are in preclinical stage.